ReviewMetabolites2026
Decoding the Metabolic Signatures of Neurodegeneration Diseases: Advances in Mass Spectrometry-Based Metabolomics.
Review in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dysregulation of multiple metabolic pathways is a potential contributor to the development of neurodegenerative diseases. Understanding early-stage metabolic alterations is crucial for identifying targets associated with disease development and progression. Recent advances in mass spectrometry-based metabolomics now allow investigators to conduct a comprehensive analysis of small-molecule metabolites in complex biological systems, providing valuable insights regarding the biochemical mechanisms underlying neurodegeneration. This review presents the latest advances in mass spectrometry-based metabolomic approaches and their applications in studying neurodegenerative diseases. We discuss methodology improvements in metabolomics, including sample preparation, chromatography separations, ionization, and fragmentation. These improvements enable broader detection and more accurate identification of metabolites. We also review developments in bioinformatics tools for large-scale data processing, structural annotation, and pathway analysis. Furthermore, the signature metabolites associated with major neurodegenerative diseases and the key metabolic pathways involved are summarized. Finally, we address current analytical and biological challenges in mass spectrometry-based metabolomics while exploring its future directions in translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.